Introduction {#Sec1}
============

Since the discovery of streptomycin in 1944 from *Streptomyces griseus,* the first antibiotic isolated from bacteria (Schatz et al. [@CR20]), Actinobacteria have obtained large attention from the scientific community, mainly due to their ability in producing a wide spectrum of bioactive compounds with antimicrobial and antitumor activities (Demain [@CR10]; Barka et al. [@CR3]). Nowadays, this class provided more than 65% of antibiotics and antifungals used in medicine; including over 10,000 bioactive compounds that were produced by the members of the genus *Streptomyces* (Bérdy [@CR4], [@CR5]; De Lima et al. [@CR9]). This genus, proposed for the first time by Waksman and Henrici ([@CR24]), belong to the Gram-positive bacteria and is ubiquitous in nature (Kämpfer [@CR14]). The classification of *Streptomyces* species is generally carried out using a polyphasic taxonomic approach, including chemotaxonomic, phenotypic, and genotypic characteristics (Anderson and Wellington [@CR1]). Currently (Status April 2020), about 841 species of the genus *Streptomyces* with valid names have been described and published so far (<https://www.bacterio.net/streptomyces.html>). Thus, several studies have been conducted to find new strains isolated from extreme habitats (Tiwari and Gupta [@CR23]; Goodfellow [@CR11]; Zhang et al. [@CR27]). To cope with the major health problem of antibiotic-resistant microorganisms, many laboratories have focused on the discovery of new bioactive molecules produced from new species belonging to this genus. In fact, whole-genome sequencing (wgs) have opened new potential for better exploitation of useful secondary metabolites produced by this genus (Harrison and Studholme [@CR12]; Lee et al. [@CR16]; Ward and Allenb [@CR25]). This fundamental technology was supported by the use of new bioinformatics tools like antiSMASH, which adds several new features, including prediction of gene cluster (Blin et al. [@CR6]).

In this study, the genome of a new strain *Streptomyces tunisialbus* DSM 105760^T^, which produces a broad spectrum of secondary metabolites with antibacterial and antifungal effects (Ayed et al. [@CR2]), was sequenced. The genome sequence of *S. tunisialbus* was established to broaden the genomic basis for functional and comparative analyses focusing on secondary metabolite biosynthesis clusters of the strain.

Materials and methods {#Sec2}
=====================

The genomic DNA was extracted from a culture grown 3 days in ISP2 medium (Shirling and Gottlieb [@CR22]), using cetyltrimethylammonium bromide (CTAB)-based method (Hopwood [@CR13]). The quality of the DNA was assessed by gel-electrophoresis, and its quantity was determined by a fluorescence-based method using the Quant-iT PicoGreen dsDNA kit (Invitrogen) and the Tecan Infinite 200 Microplate Reader (Tecan Deutschland GmbH). For sequencing of the *S. tunisialbus* DSM 105760^T^ genome, 4 μg of purified DNA was used to generate a paired library (TruSeq DNA PCR-Free Library Prep Kit, Illumina). The draft genome sequence of strain *S. tunisialbus* was established by sequencing on an Illumina MiSeq system. To assemble the obtained and processed reads, the GS de novo Assembler software version 2.8 (Roche, Mannheim, Germany) with default setting was applied as recently described (Yücel et al. [@CR26]). Annotation of the draft genome was performed by applying the GenDB 2.0 system (Meyer et al. [@CR18]) and Prokka version 1.11 (Seemann [@CR21]). To identify clusters involved in secondary metabolite biosynthesis, the annotated genome was analyzed by applying antiSMASH 5.1.2 (Blin et al. [@CR6]). Based on the 16S analysis in Ayed et al., *S. varsoviensis* NRRL ISP-5346 was determined as closest relative with a sequenced genome. *S. varsoviensis* NRRL ISP-5346 was found to produce multiple hygrolide sub-families, e.g., hygrobafilomycins (JBIR-100 and hygrobafilomycin) and bafilomycins (bafilomycins C1 and D) (Molloy et al. [@CR19]). Finally, comparative genome analysis for *S. tunisialbus* DSM 105760^T^ and *S. varsoviensis* NRRL ISP-5346 was performed by means of the comparative genomics tool EDGAR (Blom et al. [@CR7], [@CR8]). To determine the relatedness between the *S. tunisialbus* DSM 105760^T^ and *S. varsoviensis* NRRL ISP-5346 (Accession number: JOBF0100001-118), an average nucleotide identity analysis (ANI), average amino acid identity analysis (AAI) (Konstantinidis and Tiedje [@CR15]) and a DDH estimation were performed as described previously (Meier-Kolthoff et al. [@CR17]).

Results and discussion {#Sec3}
======================

The MiSeq sequencing run (2 × 300 bp) resulted in 2,092,356 reads yielding approx. 627 Mb sequence information for the sample representing on average a coverage of about 90-fold. The final draft genome established by the GS Assembler software (version 2.8, Roche) consists of 35 contigs (N50: 455,831 bp) and 20 scaffolds (N50: 678,417 bp). The annotation of the draft genome of *S. tunisialbus* showed a linear chromosome which has a size of 6,880,753 bp and encodes 5802 protein-coding sequences (CDS)s. The chromosome also contains 72 tRNA genes and eight rRNA operons (16S-23S-5S rRNA). The average GC content is 71.85% (Table [1](#Tab1){ref-type="table"}).Table 1General features of *S. tunisialbus* DSM 105760^T^ and *S. varsoviensis* NRRL ISP-5346Features*S. tunisialbus* DSM 105760^T^*S. varsoviensis* NRRL ISP-5346Length (bp)6,880,7538,588,807StatusDraft genome (35 contigs)Draft genome (118 contigs)G + C content (%)71.8572.40CDS58027229rRNAs operons8NAtRNAs genes7268

An ANI value of 84.93%, an AAI value of 87.43% and a DDH value of 25.00% were calculated for *S. tunisialbus* DSM 105760^T^ and *S. varsoviensis* NRRL ISP-5346. High ANI, AAI values (above 95%) and high DDH estimations (Formula 2 above 70%) were usually observed for bacterial isolates representing the same species and are considered to indicate bacterial species demarcation previously (Konstantinidis and Tiedje [@CR15]). Therefore, both strains are closely related, but do not belong to the same species.

By applying EDGAR, a comparative analysis was performed for *S. tunisialbus* DSM 105760^T^ and *S. varsoviensis* NRRL ISP-5346. It appeared that 3830 genes corresponding to 66% and 55% of all genes identified in both draft genomes represent the core set of genes shared by both isolates. These core genes mainly encode for housekeeping functions, e.g., glycolysis. However, *S. tunisialbus* DSM 105760^T^ possesses 1972 singletons, whereas 3062 singletons were identified for *S. varsoviensis* NRRL ISP-5346. Most of the *S. tunisialbus* DSM 105760^T^ singletons were annotated as 'hypothetical' genes or transposases. However, genes encoding enzymes potentially involved in the synthesis of secondary metabolites were identified within the unique genes of *S. tunisialbus* DSM 105760^T^. In addition, a few unique genes encoding for different cytochromes were found. For *S. varsoviensis* NRRL ISP-5346, the clusters found to produce hygrobafilomycins (JBIR-100 and hygrobafilomycin) and bafilomycins (bafilomycins C1 and D) were unique.

To identify all clusters involved in secondary metabolite biosynthesis, the *S. tunisialbus* DSM 105760^T^ genome was analyzed by means of antiSMASH 5.1.2. The platform revealed the presence of 34 predicted gene clusters encode for potential secondary metabolites, such as antibiotics, antitumor compounds, fungicide, and lantibiotics. Likewise, six of these gene clusters are terpenes, such 2-methylisoborneol \[100%\] a volatile organic compound well known for its biological activity, two for melanin biosynthesis and one for Ectoine (Table [2](#Tab2){ref-type="table"}). *S. varsoviensis* NRRL ISP-5346 has a similar portfolio of secondary metabolite clusters (Table [3](#Tab3){ref-type="table"}).Table 2Secondary metabolite cluster of *S. tunisialbus* DSM 105760^T^RegionTypeMost similar known clusterRegion 1NRPS-like,lassopeptideCitrulassin B100.00%Region 2Terpene2-Methylisoborneol100.00%Region 3T2PKS, T1PKS, NRPS, terpeneJBIR-76/JBIR-7768.00%Region 4NRPSC-10277.00%Region 5TerpeneCalicheamicin2.00%Region 6EctoineEctoine100.00%Region 7LanthipeptideSapB75.00%Region 8LinaridinPentostatine/vidarabine12.00%Region 9MelaninMelanin28.00%Region 10MelaninMelanin28.00%Region 11TerpeneAristeromycin6.00%Region 12LassopeptideLagmysin60.00%Region 13T3PKSHerboxidiene5.00%Region 14T3PKS, ladderaneVazabitide A28.00%Region 15ButyrolactoneGriseoviridin/fijimycin A8.00%Region 16T1PKSElaiophylin8.00%Region 17T1PKSGuadinomine7.00%Region 18T1PKS, thiopeptide, LAP, NRPS-like, terpene, NRPSAureothin100.00%Region 19hglE-KSa201a5.00%Region 20Terpene2-Methylisoborneol75.00%Region 21hglE-KS, T3PKSAlkylresorcinol100.00%Region 22NRPS, T1PKS, terpeneAlthiomycin100.00%Region 23Bacteriocin, NRPSKirromycin16.00%Region 24T1PKS, Terpene, bacteriocinNystatin A163.00%Region 25NRPSDeimino-antipain66.00%Region 26NRPS, terpene, T1PKS, transAT-PKS, PKS-likeNetropsin100.00%Region 27SiderophoreVibrioferrin18.00%Region 28TerpeneAsukamycin4.00%Region 29TerpeneHopene69.00%Region 30IndoleAT2433-A114.00%Region 31ButyrolactoneRegion 32NRPSBacillibactin46.00%Region 33T1PKS, NRPS, ladderane, arylpolyene, NRPS-likeAtratumycin55.00%Region 34siderophoreTable 3Secondary metabolite cluster of *S. varsoviensis* NRRL ISP-5346RegionTypeMost similar known clusterRegion 1Terpene, T1PKS, NRPS-like, phosphonate, nucleoside, lanthipeptidePhosphinothricintripeptide17.00%Region 2NRPS-like, T1PKSMiharamycin A/miharamycin B40.00%Region 3PKS-likeA-201A12.00%Region 4TerpeneRegion 5NRPSIsocomplestatin50.00%Region 6LanthipeptideAmfS80.00%Region 7LassopeptideAnantin B1/anantin B240.00%Region 8Furan, NRPSFicellomycin3.00%Region 9NRPS-like, NRPSFriulimicin A/friulimicin B/friulimicin C/friulimicin D27.00%Region 10AmglyccyclRegion 11NRPSStreptobactin47.00%Region 12AmglyccyclHygromycin A51.00%Region 13Fused, NRPS-like, TfuA-related, NRPS, T1PKSThiovarsolin A/thiovarsolin B/thiovarsolin C/thiovarsolin D83.00%Region 14NRPSrimosamide42.00%Region 15T2PKS,PKS-like, oligosaccharide, LAPDutomycin36.00%Region 16BacteriocinRegion 17TerpeneRegion 18hglE-KS, T1PKSTetronasin9.00%Region 19LanthipeptideRegion 20EctoineEctoine100.00%Region 21NRPS, T2PKSKosinostatin6.00%Region 22LAP, thiopeptideJomthonic acid A/jomthonic acid B/jomthonic acid C5.00%Region 23Thiopeptide, LAPRegion 24TerpeneAnsamitocin P-34.00%Region 25NRPS,CDPSPurincyclamide100.00%Region 26T1PKSChlorizidine A57.00%Region 27LanthipeptideRegion 28NRPS, T3PKSFeglymycin42.00%Region 29T1PKS, NRPS, aminocoumarinBafilomycin B183.00%Region 30CDPSRegion 31TerpeneEbelactone5.00%Region 32SiderophoreRegion 33SiderophoreFicellomycin3.00%Region 34SiderophoreRegion 35TerpeneHopene61.00%Region 36BacteriocinRegion 37NRPS

The presence of a large number of cryptic secondary metabolite gene clusters in its genome, offers unsuspected potential for synthesizing bioactive compounds. In addition, our study shows that sequencing of new strains allows the discovery of new secondary metabolites relevant in ecology, biotechnology and medicine.
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